EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario
Abstract
Authors
A. Meijer A.J. Omar Alsaleh